Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Operating Margin %: 23.39% (As of Dec. 2025)


FRA:I54 Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
79 GF Score
Price €4.64
GF Value €3.59
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co Operating Margin %?

Biocytogen Pharmaceuticals (Beijing) Co FRA:I54 -2.11% 79 Operating Margin % is 23.39% as of Dec. 2025. GuruFocus rates FRA:I54 with a GF Score™ of 79/100 and a GF Value™ of €3.59 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Biocytogen Pharmaceuticals (Beijing) Co ranks better than 88.24% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Biocytogen Pharmaceuticals (Beijing) Co's Operating Income for the six months ended in Dec. 2025 was €21.5 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Revenue for the six months ended in Dec. 2025 was €91.9 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % for the quarter that ended in Dec. 2025 was 23.39%.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % or its related term are showing as below:

FRA:I54' s Operating Margin % Range Over the Past 10 Years
Min: -146.31   Med: -77.39   Max: 20.22
Current: 20.22


FRA:I54's Operating Margin % is ranked better than
88.24% of 944 companies
in the Biotechnology industry
Industry Median: -86.83 vs FRA:I54: 20.22

Biocytogen Pharmaceuticals (Beijing) Co's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Biocytogen Pharmaceuticals (Beijing) Co's Operating Income for the six months ended in Dec. 2025 was €21.5 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was €33.7 Mil.

Warning Sign:

Biocytogen Pharmaceuticals (Beijing) Co Ltd has recorded a loss in operating income at least once over the past 3 years.


Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Biocytogen Pharmaceuticals (Beijing) Co Operating Margin % Related Terms


Biocytogen Pharmaceuticals (Beijing) Co Operating Margin % Historical Data

* Premium members only.

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co Operating Margin % Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -146.31 -112.77 -42.01 15.32 20.21

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -37.16 1.84 25.03 16.32 23.39

FRA:I54 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocytogen Pharmaceuticals (Beijing) Co Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % falls into.


FRA:I54
79GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocytogen Pharmaceuticals (Beijing) Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=33.781 / 167.183
=20.21 %

Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=21.494 / 91.89
=23.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 23.39% mean?
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a Operating Margin % of 23.39% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #111 out of 944 companies in the Biotechnology industry, placing it in the top 11.8%.
Is Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Operating Margin % is 23.39%. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #111 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #111 out of 944 companies for Operating Margin %. This places Biocytogen Pharmaceuticals (Beijing) Co in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. Biocytogen Pharmaceuticals (Beijing) Co's current Operating Margin % is 23.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €4.64 — trading 29.2% above its estimated fair value. The current Operating Margin % is 23.39%. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current Operating Margin % is 23.39% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of €4.64 is trading 29.2% above its estimated GF Value™ of €3.59. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Modestly Overvalued.

Key valuation signals for FRA:I54:

  • Operating Margin %: 23.39%
  • GF Value™: €3.59 vs. price of €4.64 (29.2% above fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong Kong688796:China
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
79GF Score

Get the complete analysis for FRA:I54

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.64
Price
€3.59
GF Value